Video

European Association of Nuclear Medicine EANM 2024 VL

Search

RaLu Trial: Sequence of Radium Then Lutetium in mCRPC Management - Kambiz Rahbar Details Oliver Sartor and Kambiz Rahbar discuss the RaLu study examining the safety and efficacy of sequential radiopharmaceutical treatments in metastatic castration-resistant prostate cancer. The discussion highlights how lutetium-PSMA therapy can be safely administered following radium treatment, with outcomes consistent across different treatment sequences and timing intervals. They examine how these...
Response and Progression Criteria for PSMA PET: Imaging Prostate Cancer Outcomes - Wolfgang Fendler Details Oliver Sartor and Wolfgang Fendler explore the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. Dr. Fendler outlines two key assessment approaches: the PPP criteria for early-stage disease focusing on lesion numbers, and the RECIP criteria for advanced disease examining tumor volume changes. The conversation highlights how PSMA PET findings corr...
Combining Lutetium-PSMA with Hormonal Therapy Enhances Prostate Cancer Treatment - Louise Emmett Details Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...